share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFM Health Sciences, LP(1.9%),PFM Health Sciences GP, LLC(1.9%), etc.

SEC announcement ·  Feb 15 05:14
Summary by Futu AI
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
On December 31, 2023, a Schedule 13G/A filing was made with the United States Securities and Exchange Commission by PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman, collectively referred to as the Reporting Persons, regarding their ownership in bluebird bio, Inc. The filing indicates that these entities and individuals collectively hold 2,042,651 shares of bluebird bio's common stock, which represents approximately 1.9% of the company's outstanding common stock as of November 3, 2023. The Reporting Persons have shared voting and dispositive power over these shares. The filing was certified as true and correct by Darren Mooney, authorized signatory, on February 14, 2024. The address for the principal business office of the Reporting Persons is in San Francisco, California. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.